Physician profile
Emily Moriarty
NPI 1619137197
$2,194.29
in general payments reported to CMS, 2019-2025
21 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $191 · 2021: $171 · 2022: $118 · 2023: $180 · 2024: $921 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $357.19 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Abbvie INC. | $243.22 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $173.02 | 2019-2021 | |
| Sight Sciences, INC. | $161.27 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $146.10 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $125.67 | 2022-2024 | Miebo, Vyzulta, Prolensa |
| Novartis Pharmaceuticals Corporation | $122.22 | 2019-2021 | |
| Dompe US, INC. | $119.91 | 2021-2025 | Oxervate |
| Alcon Vision LLC | $118.35 | 2019-2025 | Tryptyr, Clareon, Rocklatan |
| Tarsus Pharmaceuticals, INC. | $106.42 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $97.14 | 2024 | Idose |
| Ocular Therapeutix, INC. | $85.21 | 2023-2024 | Dextenza |
| Mallinckrodt Hospital Products INC. | $68.37 | 2021-2025 | Acthar |
| Alimera Sciences, INC. | $58.31 | 2021 | |
| Allergan, INC. | $54.83 | 2020-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $44.73 | 2019-2020 | |
| Harrow Eye, LLC | $33.09 | 2024 | Vevye, Iheezo |
| Shire North American Group INC | $24.55 | 2019 | |
| Coherus Oncology, INC. | $22.87 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $16.89 | 2020 | |
| Oyster Point Pharma, INC. | $14.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Moriarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.